Across TCGA pan-cancer cohorts, FRG2B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FRG2B data layer compared with 13 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FRG2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FRG2B expression acts as an unfavorable survival marker.
LUAD are the cancer types where FRG2B Mutation most reproducibly stratifies survival.